NDAORALTABLETPriority Review
Approved
Jan 2023
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Mechanism of Action
Bruton's Tyrosine Kinase Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Clinical Trials (5)
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Started Mar 2026
150 enrolled
Chronic Lymphocytic LeukemiaLymphoma, Small Lymphocytic
Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial
Started Nov 2025
22 enrolled
Grade 1 Follicular LymphomaGrade 2 Follicular LymphomaGrade 3a Follicular Lymphoma+2 more
A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
Started Nov 2025
40 enrolled
Waldenstrom MacroglobulinemiaLymphoplasmacytic Lymphoma
Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell Lymphoma
Started Sep 2025
50 enrolled
Mantle Cell Lymphoma (MCL)
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Started Sep 2025
500 enrolled
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Loss of Exclusivity
LOE Date
Sep 14, 2041
189 months away
Patent Expiry
Sep 14, 2041
Exclusivity Expiry
Dec 1, 2030